Specifically, increased GPNMB expression has been linked to poorer prognosis in breast cancer patients [109], and mutations in the GPNMB gene have been named as causal of the skin pigmentation disorder amyloidosis cutis dyschromica (ACD) [110]. This evidence concerns the gene GPNMB and granular corneal dystrophy type II.